TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 18800460
Drug: losartan 50
Normalized name: LOSARTAN 50MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: losartan 50 mg
Study: 7583899
Drug: Clonidine-bupivacaine-morphine
Normalized name: Clonidine
DrugBank: Clonidine (DB00575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clonidine-bupivacaine-morphine
Study: 7583899
Drug: Bupivacaine-morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine-morphine
Study: 19181448
Drug: Any type
Normalized name: collagen type I
Approvals — FDA: no, EMA: no, PMDA: no
Description: Any type of opioid prescriptions for >or=90 days
Study: 19181448
Drug: No opioid
Approvals — FDA: no, EMA: no, PMDA: no
Description: No opioid prescriptions
Study: 17188618
Drug: Oral steroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral steroids and oral cyclophosphamide (CYC) (maximum total dose 150 mg/kg) followed by oral methotrexate (MTX) (12.5 mg/m(2)/week) for maintenance.
Study: 17188618
Drug: Oral steroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral steroids and methotrexate (MTX) (12.5 mg/m(2)/week).
Study: 10856105
Drug: High-dose interferon
Normalized name: interferon-beta
DrugBank: Human interferon beta (DB14999)
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose interferon alfa-2b (HDI) for 1 year
Study: 11331315
Drug: GM2 conjugated
Normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GM2 conjugated to keyhole limpet hemocyanin and administered with QS-21 (GMK) for 96 weeks
Study: 9205817
Drug: Intravenous infusion
Normalized name: intravenous infusion pump accessory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of zolmitriptan (3.5 mg)
Study: 9205817
Drug: Oral tablet
Normalized name: Oral Tablet
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral tablet of zolmitriptan (10 mg)
Study: 9205817
Drug: Administration of
Normalized name: IV solutions used in parenteral administration of fluids, electrolytes and nutrients
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of 25 mg [14C]-zolmitriptan capsule
Study: 9205817
Drug: Intravenous dosing
Normalized name: Metered Dose Inhaler
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous dosing of zolmitriptan
Study: 8434963
Drug: NK 622
Normalized name: NK Cells
DrugBank: Natural Killer Cell (DB15721)
Approvals — FDA: no, EMA: no, PMDA: no
Description: NK 622 (toremifene citrate) 40 mg/day
Study: 23410986
Drug: VES‐ODT (orally
Approvals — FDA: no, EMA: no, PMDA: no
Description: VES‐ODT (orally disintegrating tablet)
Study: 23410986
Drug: VES‐CT (conventional
Approvals — FDA: no, EMA: no, PMDA: no
Description: VES‐CT (conventional tablet)
Study: 14998427
Drug: 3-day training
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3-day training program on rational pharmacotherapy
Study: 11463766
Drug: Angiotensin-(1-7) infusion
Normalized name: Angiotensin (1-7)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Angiotensin-(1-7) infusion (10(-10), 10(-9), and 10(-8) mol/min for 5 minutes)
Study: 11463766
Drug: N(G)-monomethyl-L-arginine (nitric
Approvals — FDA: no, EMA: no, PMDA: no
Description: N(G)-monomethyl-L-arginine (nitric oxide synthesis inhibitor)
Study: 2567745
Drug: Performance-based treatment
Normalized name: Perform
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Performance-based treatment for some phobic areas
Study: 4909766
Drug: High oral
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High oral doses of marihuana extract (1 (‐)‐Delta(1)‐tetrahydrocannabinol)
Study: 28025037
Drug: Inhaled tobramycin
Normalized name: tobramycin Inhalation Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled tobramycin with azithromycin
Study: 28025037
Drug: Inhaled aztreonam
Normalized name: aztreonam Inhalation Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled aztreonam after tobramycin
Study: 28025037
Drug: Inhaled tobramycin
Normalized name: tobramycin Inhalation Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled tobramycin without azithromycin
Study: 21248785
Drug: Amlodipine/valsartan/hydrochlorothiazide (10/320/25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine/valsartan/hydrochlorothiazide (10/320/25 mg)
Study: 21248785
Drug: Dual therapies
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual therapies (valsartan/hydrochlorothiazide, amlodipine/valsartan, amlodipine/hydrochlorothiazide)
Study: 17971827
Drug: Iron and
Normalized name: beef,iron and wine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron and folic acid (30 mg) with micronutrients
Study: 17971827
Drug: Iron and
Normalized name: beef,iron and wine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron and folic acid (30 mg) without micronutrients
Study: 17380489
Drug: 10 cm2
Normalized name: thrombin/cal/cmc/gel/dress,hem 10 cm2 TOPICAL PADS, MEDICATED (EA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 cm2 rivastigmine patch
Study: 17380489
Drug: 20 cm2
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 cm2 rivastigmine patch
Study: 21309961
Drug: 12 mg/day
Normalized name: EMSAM 12 MG/Day 24HR Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12 mg/day rivastigmine capsules
Study: 17380489
Drug: All patch
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All patch sizes (5, 10, 15, and 20 cm2)
Study: 7836964
Drug: Chlorpromazine (CHLP,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorpromazine (CHLP, 50 mg, i.m.)
Study: 3354865
Drug: Nalbuphine hydrochloride
Normalized name: Nalbuphine Hydrochloride
DrugBank: Nalbuphine (DB00844)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nalbuphine hydrochloride 0.2 mg/kg
Study: 26599904
Drug: Icotinib (125
Approvals — FDA: no, EMA: no, PMDA: no
Description: Icotinib (125 mg tablet, three times per day)
Study: 12858462
Drug: 20 micro
Normalized name: Calcifediol 20 microgram oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 micro g of teriparatide by daily self-injection
Study: 12858462
Drug: 40 micro
Normalized name: Travoprost 40 microgram/mL eye drops
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 micro g of teriparatide by daily self-injection
Study: 7753338
Drug: Corticotropin-releasing hormone
Normalized name: corticotropin-releasing hormone
DrugBank: Corticorelin (DB05394)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticotropin-releasing hormone (CRH) infusion (1 microgram/kg/h) with metyrapone
Study: 30184222
Drug: Complementary food
Normalized name: ALLERGENIC EXTRACT, FOOD, WHEAT
DrugBank: Wheat (DB10579)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Complementary food supplements (CFSs)
Study: 27297847
Drug: Eliminating patient
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eliminating patient copayment for P2Y12 receptor inhibitor therapy
Study: 24685421
Drug: Offer of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Offer of treatment by a homeopath
Study: 8980935
Drug: RAT2 (ranitidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: RAT2 (ranitidine 300 mg twice daily, amoxycillin 1000 mg twice daily, plus tinidazole 500 mg twice daily for 2 weeks)
Study: 8980935
Drug: RA2 (ranitidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: RA2 (ranitidine 300 mg twice daily plus amoxycillin 1000 mg twice daily for 2 weeks)
Study: 1727754
Drug: Tube-fed nutrition
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tube-fed nutrition (1.5 g/kg protein and 167 kJ/kg daily)
Study: 25967526
Drug: Travoprost 0.004%
Normalized name: TRAVOPROST 0.004% SOLN,OPH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Travoprost 0.004% preserved with SofZia (TRAVATAN Z solution)
Study: 21987393
Drug: Intramuscular interferon
Normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular interferon beta-1a (immediate-treatment group)
Study: 21987393
Drug: Placebo (delayed-treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (delayed-treatment group)
Study: 17873022
Drug: Ghrelin infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ghrelin infusion at a rate of 5 pmol/kg per minute for 180 min
Study: 10512130
Drug: Paclitaxel (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paclitaxel (60 mg/m2) given as a 3‐h infusion on days 1, 8, 15, 22, 29 and 36; CHART started on day 15 with 150 cGy/fraction given three times a day for a total dose of 54 Gy in 12 days.
Study: 7555483
Drug: Programmable implantable
Normalized name: PUMP,LUTREPULSE PROGRAMMABLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Programmable implantable pump therapy
Study: 6113885
Drug: Fazadinium bromide
Normalized name: fazadinium bromide
DrugBank: Fazadinium bromide (DB13745)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fazadinium bromide 1 mg . kg‐1
Study: 6113885
Drug: Fazadinium bromide
Normalized name: fazadinium bromide
DrugBank: Fazadinium bromide (DB13745)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fazadinium bromide 1.5 mg . kg‐1
Study: 20236365
Drug: Uridine (36
Approvals — FDA: no, EMA: no, PMDA: no
Description: Uridine (36 g tid on 10 consecutive days per month; n=10)
Study: 20236365
Drug: Pravastatin (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pravastatin (40 mg nocte; n=12)
Study: 17401044
Drug: 0.25 mg
Normalized name: biotin 0.25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.25 mg dexamethasone suppression test
Study: 15707766
Drug: Saffron 30
Normalized name: SAFFRON
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saffron 30 mg/day (BD)
Study: 15707766
Drug: Fluoxetine 20
Normalized name: fluoxetine 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine 20 mg/day (BD)
Study: 12123331
Drug: IRIFAFU (Irinotecan
Approvals — FDA: no, EMA: no, PMDA: no
Description: IRIFAFU (Irinotecan 200 mg/m2 + Levo-FA 250 mg/m2 + 5-FU 850 mg/m2)
Study: 12123331
Drug: MTXFAFU (Methotrexate
Approvals — FDA: no, EMA: no, PMDA: no
Description: MTXFAFU (Methotrexate 750 mg/m2 + Levo-FA 250 mg/m2 + 5-FU 800 mg/m2)
Study: 20937929
Drug: 0.625 mg/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.625 mg/d of conjugated equine estrogens (CEE)
Study: 8569016
Drug: E+P regimens
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: E+P regimens (0.625 mg/d of CEE plus 10 mg/d of MPA for the first 12 days, 0.625 mg/d of CEE plus 2.5 mg/d of MPA, or 0.625 mg/d of CEE plus 200 mg/d of MP for the first 12 days)
Study: 8569016
Drug: 0.625 mg/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.625 mg/d of CEE
Study: 6122852
Drug: 2% phenoxetol
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% phenoxetol and 0.2% chlorhexidine cream
Study: 17559733
Drug: Sitagliptin 25
Normalized name: SITagliptin 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sitagliptin 25 mg once-daily
Study: 17559733
Drug: Sitagliptin 50
Normalized name: SITagliptin 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sitagliptin 50 mg once-daily
Study: 17130197
Drug: Sitagliptin 100
Normalized name: SITagliptin 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sitagliptin 100 mg once-daily
Study: 17559733
Drug: Sitagliptin 50
Normalized name: SITagliptin 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sitagliptin 50 mg twice-daily
Study: 8917000
Drug: Oral misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral misoprostol 400 micrograms
Study: 11207490
Drug: Intravenous syntocinon
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous syntocinon 10 IU
Study: 8042809
Drug: Inhaled albuterol
Normalized name: albuterol Inhalation Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled albuterol (360 micrograms)
Study: 8042809
Drug: Inhaled albuterol
Normalized name: albuterol Inhalation Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled albuterol and ipratropium bromide
Study: 24152211
Drug: Bronchodilator treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bronchodilator treatment
Study: 21067350
Drug: ceftaroline 600
Normalized name: ceftaroline 600 mg intravenous powder for injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: ceftaroline 600 mg every 12 h for 5-7 days
Study: 21067350
Drug: ceftriaxone 1
Normalized name: ceftriaxone 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: ceftriaxone 1 g every 24 h for 5-7 days
Study: 12394436
Drug: Stapled rectal
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Stapled rectal mucosectomy
Study: 2247767
Drug: Control (conventional
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (conventional antihypertensive treatment)
Study: 28605207
Drug: Pain Neurophysiology
Normalized name: Dermoplast Pain
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pain Neurophysiology Education (PNE) treatment
Study: 26842122
Drug: Isoproterenol (ISO-stress)
Normalized name: isoproterenol sulfate Metered Dose Inhaler [Medihaler-Iso]
DrugBank: Isoprenaline (DB01064)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isoproterenol (ISO-stress) infusion
Study: 19647866
Drug: Raltegravir (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Raltegravir (400 mg oral twice daily)
Study: 19647866
Drug: Efavirenz (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Efavirenz (600 mg oral once daily)
Study: 8519719
Drug: Bupivacaine 0.25%
Normalized name: BUPIVACAINE 0.25%/NS INJ 400ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine 0.25% infused at a rate of 5 mL/h
Study: 8519719
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no bupivacaine infusion)
Study: 2226911
Drug: Cyclic regimen
Normalized name: cyclic AMP
DrugBank: Cyclic adenosine monophosphate (DB02527)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclic regimen of 0.625 mg/d of conjugated equine estrogens for 25 days/month and 10 mg medroxyprogesterone acetate for the last 13 days of E
Study: 2226911
Drug: Continuous regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous regimen of 0.625 mg/d of conjugated equine estrogens along with 5 mg medroxyprogesterone acetate
Study: 2226911
Drug: Continuous regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous regimen of 0.625 mg/d of conjugated equine estrogens along with 10 mg medroxyprogesterone acetate
Study: 27405596
Drug: Convalescent plasma
Normalized name: Convalescent plasma
DrugBank: COVID-19 convalescent plasma (DB15692)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Convalescent plasma therapy for MERS-CoV infection
Study: 23319466
Drug: Mean daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mean daily counts per minute (CPM)
Study: 23319466
Drug: Mean daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mean daily steps per day
Study: 22561385
Drug: Ultrasonography-guided corticosteroid
Normalized name: abiraterone and corticosteroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasonography-guided corticosteroid injections
Study: 22561385
Drug: Blind corticosteroid
Normalized name: Io-Blend
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blind corticosteroid injections
Study: 18051910
Drug: SCTXLC 0.26
Approvals — FDA: no, EMA: no, PMDA: no
Description: SCTXLC 0.26 g (4 capsules, three times a day) for 28 days
Study: 18051910
Drug: CCTXLC 0.38
Approvals — FDA: no, EMA: no, PMDA: no
Description: CCTXLC 0.38 g (4 capsules, three times a day) for 28 days
Study: 12042618
Drug: Intragraft 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intragraft 200 µg verapamil
Study: 7876926
Drug: Intravenous nutrient
Normalized name: Votrient
DrugBank: Pazopanib (DB06589)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Intravenous nutrient mixture
Study: 7876926
Drug: Intravenous nutrients
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous nutrients
Study: 350512
Drug: Tolamolol 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tolamolol 50 mg
Study: 6896183
Drug: Tolamolol 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tolamolol 100 mg
Study: 22140497
Drug: verum (local
Approvals — FDA: no, EMA: no, PMDA: no
Description: verum (local anaesthetic) injection
Study: 22140497
Drug: placebo (sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo (sodium chloride) injection
Study: 16860174
Drug: NA/EE 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: NA/EE 0.5 mg/2.5 μg
Study: 7692110
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg finasteride
Study: 7512661
Drug: Extension study
Normalized name: EXTENSION TUBES
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extension study (5 mg finasteride for all patients)
Study: 29402767
Drug: Bardoxolone methyl
Normalized name: Bardoxolone methyl
DrugBank: Bardoxolone methyl (DB05983)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bardoxolone methyl (20 mg once daily)
Study: 18425402
Drug: Hydrochlorothiazide 12.5
Normalized name: hydrochlorothiazide 12.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrochlorothiazide 12.5 or 25 mg/day
Study: 7380205
Drug: Spironolactone (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spironolactone (200 mg/day)
Study: 10792338
Drug: Cyproterone acetate
Normalized name: cyproterone acetate
DrugBank: Cyproterone acetate (DB04839)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyproterone acetate (CPA) (50 mg/day) with ethinyl oestradiol (35 microgram/day)
Study: 6895140
Drug: antirheumatic drugs
Normalized name: Quinolines, antirheumatic drugs
Approvals — FDA: no, EMA: no, PMDA: no
Description: antirheumatic drugs
Study: 26658900
Drug: High phenolic
Normalized name: Phenol
DrugBank: Phenol (DB03255)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: High phenolic content olive oil (HPC) - 366 mg/kg
Study: 26658900
Drug: Low phenolic
Normalized name: Phenol
DrugBank: Phenol (DB03255)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Low phenolic content olive oil (LPC) - 2.7 mg/kg
Study: 23751152
Drug: Sublingual 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual 400 μg misoprostol and 100 mg diclofenac
Study: 17652452
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg diclofenac alone (control group)
Study: 15080356
Drug: Submucosal midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Submucosal midazolam (0.2 mg/kg) and oral chloral hydrate (50 mg/kg)
Study: 15080356
Drug: Oral chloral
Normalized name: Chloral Hydrate
DrugBank: Chloral hydrate (DB01563)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral chloral hydrate (50 mg/kg) and submucosal saline placebo
Study: 31743165
Drug: Methylprednisolone (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylprednisolone (250 mg IV, 2 doses)
Study: 28460864
Drug: Natural history
Approvals — FDA: no, EMA: no, PMDA: no
Description: Natural history group (no therapy)
Study: 19925567
Drug: Sertaconazole cream
Normalized name: sertaconazole Topical Cream
DrugBank: Sertaconazole (DB01153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sertaconazole cream (2%) applied topically twice daily for 2 weeks
Study: 19925567
Drug: Miconazole cream
Normalized name: Miconazole Nitrate 2% Topical application Cream [CAREALL MICONAZOLE CREAM]
DrugBank: Miconazole (DB01110)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Miconazole cream (2%) applied topically twice daily for 2 weeks
Study: 18697865
Drug: E2 supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: E2 supplementation (transdermal for 3 weeks)
Study: 18697865
Drug: Pilot iv
Normalized name: Picot
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pilot iv bolus ghrelin infusions
Study: 14556812
Drug: Tamoxifen citrate
Normalized name: Tamoxifen Citrate
DrugBank: Tamoxifen (DB00675)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tamoxifen citrate 20 mg/d and testosterone undecanoate 120 mg/d (n = 106)
Study: 14556812
Drug: Placebo treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment (n = 106)
Study: 14556812
Drug: Active treatment
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active treatment group (n = 106)
Study: 3966649
Drug: 30 ml
Normalized name: Vial M/T 30 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 ml of 0.3 molar sodium citrate less than 60 min preoperatively (n = 11)
Study: 3966649
Drug: 30 ml
Normalized name: Vial M/T 30 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 ml of 0.3 molar sodium citrate longer than 60 min preoperatively (n = 11)
Study: 3966649
Drug: No antacid
Approvals — FDA: no, EMA: no, PMDA: no
Description: No antacid (control group, n = 10)
Study: 27183035
Drug: Physical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physical therapy (2 times per week for 6 weeks, followed by 6 weeks of monitored home exercise)
Study: 17096501
Drug: Intra-articular hyaluronic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-articular hyaluronic acid (HA) injection
Study: 5443056
Drug: Silastic vaginal
Normalized name: CATHETER SILASTIC 14FR 5CC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Silastic vaginal ring without medication (Control)
Study: 30985624
Drug: Hybrid treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hybrid treatment (n=58, 10-16 sessions)
Study: 30985624
Drug: iCBT (n=57;
Approvals — FDA: no, EMA: no, PMDA: no
Description: iCBT (n=57; 8 treatment modules)
Study: 21355444
Drug: Test formulation
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test formulation of pioglitazone 45 mg
Study: 21355444
Drug: Reference product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference product of pioglitazone 45 mg
Study: 19954060
Drug: mRNA expression
Normalized name: SARS-CoV-2 (COVID-19) vaccine, mRNA-1273 Injectable Suspension [Spikevax]
Approvals — FDA: no, EMA: no, PMDA: no
Description: mRNA expression of functional genes of neutrophils, monophagocytes, IFN regulating factors, TNF, adhesion molecules and T cells in PE patients
Study: 10834777
Drug: Bupivacaine 8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine 8 mg + Fentanyl 10 microg
Study: 10834777
Drug: Bupivacaine 10
Normalized name: BUPivacaine 100 mg parenteral implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine 10 mg + Fentanyl 10 microg
Study: 10834777
Drug: Bupivacaine 12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine 12 mg
Study: 10834777
Drug: Bupivacaine 12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine 12 mg + Fentanyl 10 microg
Study: 7681510
Drug: Felodipine after
Normalized name: Felodipine
DrugBank: Felodipine (DB01023)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Felodipine after 1 week of oral ramipril
Study: 3092654
Drug: Ranitidine 150
Normalized name: ranitidine 150 MG
DrugBank: Ranitidine (DB00863)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ranitidine 150 mg intragastrically
Study: 31721089
Drug: Cinnamon capsules
DrugBank: Cinnamon (DB10520)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cinnamon capsules for 60 days